Thomas Burke
Amministratore Delegato presso Hennepin Life Sciences LLC
Profilo
Thomas Burke currently works at Hennepin Life Sciences LLC, as Chief Executive Officer & Director and Rovermed Biosciences LLC, as Director.
Posizioni attive di Thomas Burke
| Società | Posizione | Inizio |
|---|---|---|
Rovermed Biosciences LLC
 Rovermed Biosciences LLC BiotechnologyHealth Technology Rovermed Biosciences LLC develops precision targeted nanocapsule technology aimed at delivering life saving drugs to the most challenging disease sites. The company was founded in 2016 and is headquartered in St. Cloud, MN. | Direttore/Membro del Consiglio | - |
Hennepin Life Sciences LLC
 Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Rovermed Biosciences LLC
Rovermed Biosciences LLC BiotechnologyHealth Technology Rovermed Biosciences LLC develops precision targeted nanocapsule technology aimed at delivering life saving drugs to the most challenging disease sites. The company was founded in 2016 and is headquartered in St. Cloud, MN. | Health Technology |
Hennepin Life Sciences LLC
Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Health Technology |
- Borsa valori
- Insiders
- Thomas Burke
